The particular interest of our lab is to understand the regulatory events that prevail in cancer cells, and detect and exploit cancer cell characteristics that could be used as basis of new cancer therapies. The approaches used in the laboratory are aimed to provide novel information on the regulation of cellular DNA damage and tumorigenesis pathways, to identify new targets for therapy, and to apply this knowledge to therapy efforts. The studies aim at a rapid transfer of findings arising from focused mechanistic studies into translational cancer research.
Wei T, Najmi SM, Liu H, Peltonen K, Kucerova A, Schneider DA, Laiho M. Small-Molecule Targeting of RNA Polymerase I Activates a Conserved Transcription Elongation Checkpoint. Cell Rep. 2018 PubMed PMID: 29642000.
Guner G, Sirajuddin P, Zheng Q, Bai B, Brodie A, Liu H, Af Hällström T, Kulac I, Laiho M, De Marzo AM. Novel Assay to Detect RNA Polymerase I Activity In Vivo. Mol Cancer Res. 2017 PMID: 28119429.
Peltonen K, Colis L, Liu H, Jäämaa S, Zhang Z, Af Hällström T, Moore HM, Sirajuddin P, Laiho M. Small molecule BMH-compounds that inhibit RNA polymerase I and cause nucleolar stress. Mol Cancer Ther. 2014 PMID: 25277384.
Bai B, Yegnasubramanian S, Wheelan SJ, Laiho M. RNA-Seq of the nucleolus reveals abundant SNORD44-derived small RNAs. PLoS One. 2014 PMID: 25203660.
Peltonen K, Colis L, Liu H, Trivedi R, Moubarek MS, Moore HM, Bai B, Rudek MA, Bieberich CJ, Laiho M. A targeting modality for destruction of RNA polymerase I that possesses anticancer activity. Cancer Cell. 2014 PMID: 24434211.